Bernard Charlotte, Balestre Eric, Coffie Patrick A, Eholie Serge Paul, Messou Eugène, Kwaghe Viviane, Okwara Benson, Sawadogo Adrien, Abo Yao, Dabis François, de Rekeneire Nathalie
INSERM, Centre INSERM U1219-Epidémiologie-Biostatistique, Bordeaux, France,
University of Bordeaux, School of Public Health (ISPED), Bordeaux, France,
HIV AIDS (Auckl). 2018 Nov 16;10:239-252. doi: 10.2147/HIV.S172198. eCollection 2018.
Reporting mortality and lost to follow-up (LTFU) by age is essential as older HIV-positive patients might be at risk of long-term effects of living with HIV and/or taking antiretroviral therapy (ART). As age effects might not be linear and might impact HIV outcomes in the oldest more severely, people living with HIV (PLHIV) aged 50-59 years and PLHIV aged >60 years were considered separately.
Seventeen adult HIV/AIDS clinics spread over nine countries in West Africa.
Data were collected within the International Epidemiological Databases to Evaluate AIDS West Africa Collaboration. ART-naïve PLHIV-1 adults aged >16 years initiating ART and attending ≥2 clinic visits were included (N=73,525). Age was divided into five groups: 16-29/30-39/40-49/50-59/≥60 years. The age effect on mortality and LTFU was evaluated with Kaplan-Meier curves and multivariable Cox proportional hazard regressions.
At month 36, 5.9% of the patients had died and 47.3% were LTFU. Patients aged ≥60 (N=1,736) and between 50-59 years old (N=6,792) had an increased risk of death in the first 36 months on ART (adjusted hazard ratio=1.66; 95% CI: 1.36-2.03 and adjusted hazard ratio=1.31; 95% CI: 1.15-1.49, respectively; reference: <30 years old). Patients ≥60 years old tend to be more often LTFU.
The oldest PLHIV presented the poorest outcomes, suggesting that the PLHIV aged >50 years old should not be considered as a unique group irrespective of their age. Tailored programs focusing on improving the care services for older PLHIV in Sub-Saharan Africa are clearly needed to improve basic program outcomes.
按年龄报告死亡率和失访情况至关重要,因为年龄较大的艾滋病毒阳性患者可能面临感染艾滋病毒和/或接受抗逆转录病毒疗法(ART)的长期影响风险。由于年龄效应可能不是线性的,且可能对年龄最大的患者的艾滋病毒治疗结果产生更严重影响,因此分别考虑了50至59岁的艾滋病毒感染者(PLHIV)和60岁以上的PLHIV。
分布在西非九个国家的17家成人艾滋病毒/艾滋病诊所。
数据收集于国际流行病学数据库西非艾滋病合作项目。纳入了16岁以上开始接受ART且至少就诊2次的未接受过ART的PLHIV-1成人(N = 73,525)。年龄分为五组:16 - 29/30 - 39/40 - 49/50 - 59/≥60岁。采用Kaplan-Meier曲线和多变量Cox比例风险回归评估年龄对死亡率和失访的影响。
在第36个月时,5.9%的患者死亡,47.3%失访。60岁及以上(N = 1,736)和50至59岁(N = 6,792)的患者在接受ART的前36个月内死亡风险增加(调整后风险比分别为1.66;95%置信区间:1.36 - 2.03和调整后风险比 = 1.31;95%置信区间:1.15 - 1.49;参照组:<30岁)。60岁及以上的患者往往更容易失访。
年龄最大的PLHIV治疗结果最差,这表明50岁以上的PLHIV不应被视为一个统一的群体而不考虑其年龄。显然需要制定针对性的项目,专注于改善撒哈拉以南非洲地区老年PLHIV的护理服务,以改善基本项目成果。